Ovarian cancer (OC) is a lethal gynecological cancer. The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway plays an important role in the regulation of cell survival, growth, and proliferation. Irregularities in the major components of the PI3K/AKT/mTOR signaling pathway are common in human cancers. Despite the availability of strong pre-clinical and clinical data of PI3K/AKT/mTOR pathway inhibitors in OC, there is no FDA approved inhibitor available for the treatment of OC. Here, we outline the importance of PI3K/AKT/mTOR signaling pathway in OC tumorigenesis, proliferation and progression, and pre-clinical and clinical experience with several PI3K/AKT/mTOR pathway inhibitors in OC.

卵巢癌（OC）是致命的妇科癌症。磷脂酰肌醇3-激酶（PI3K）/ AKT /哺乳动物雷帕霉素靶标（mTOR）信号通路在调节细胞存活，生长和增殖中起重要作用。PI3K / AKT / mTOR信号通路主要成分的不规则性在人类癌症中很常见。尽管在OC中可获得强大的PI3K / AKT / mTOR途径抑制剂的临床前和临床数据，但尚无FDA批准的可用于OC治疗的抑制剂。在这里，我们概述了PI3K / AKT / mTOR信号通路在OC肿瘤发生，增殖和进展中的重要性，以及在OC中使用几种PI3K / AKT / mTOR通路抑制剂的临床前和临床经验。